CRISPR Therapeutics AG
CRSP50.855USD
-2.495-4.68%
Horário de mercado （ET）Cotações atrasadas em 15 min
4.77BValor de mercado
PerdaP/L TTM
Mais detalhes de CRISPR Therapeutics AG Empresa
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Informações de CRISPR Therapeutics AG
Código da empresaCRSP
Nome da EmpresaCRISPR Therapeutics AG
Data de listagemOct 19, 2016
CEOKulkarni (Samarth)
Número de funcionários393
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 19
EndereçoBaarerstrasse 14
CidadeZUG
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísSwitzerland
Código postalCH-6300
Telefone41415613279
Sitehttps://crisprtx.com/
Código da empresaCRSP
Data de listagemOct 19, 2016
CEOKulkarni (Samarth)
Executivos da empresa CRISPR Therapeutics AG
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
219.82K
-90000.00%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
3.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
--
--
Mr. Susan Kim
Mr. Susan Kim
Investor Relations
Investor Relations
--
--
Dr. Douglas A. (Doug) Treco, Ph.D.
Dr. Douglas A. (Doug) Treco, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. H. Edward Fleming, Jr., M.D.
Dr. H. Edward Fleming, Jr., M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
219.82K
-90000.00%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
3.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: seg, 17 de nov
Atualizado em: seg, 17 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
ARK Investment Management LLC
10.27%
BlackRock Institutional Trust Company, N.A.
6.56%
Capital International Investors
5.93%
Orbis Investment Management Ltd.
5.23%
State Street Investment Management (US)
4.20%
Outro
67.81%
Investidores
Investidores
Proporção
ARK Investment Management LLC
10.27%
BlackRock Institutional Trust Company, N.A.
6.56%
Capital International Investors
5.93%
Orbis Investment Management Ltd.
5.23%
State Street Investment Management (US)
4.20%
Outro
67.81%
Tipos de investidores
Investidores
Proporção
Investment Advisor
43.88%
Investment Advisor/Hedge Fund
23.60%
Venture Capital
3.41%
Research Firm
3.13%
Hedge Fund
2.56%
Individual Investor
1.57%
Bank and Trust
0.52%
Pension Fund
0.44%
Sovereign Wealth Fund
0.43%
Outro
20.47%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
980
79.52M
84.90%
+75.16K
2025Q3
1019
79.46M
89.59%
+5.57M
2025Q2
986
73.90M
82.20%
+7.69M
2025Q1
943
66.36M
83.61%
-5.70M
2024Q4
951
66.15M
80.53%
+2.60M
2024Q3
955
62.43M
76.50%
+840.55K
2024Q2
969
61.63M
76.06%
+573.40K
2024Q1
979
61.11M
68.18%
+3.34M
2023Q4
980
54.61M
75.07%
+613.05K
2023Q3
983
54.08M
76.54%
+343.99K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
ARK Investment Management LLC
9.79M
10.27%
-395.62K
-3.89%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.25M
6.56%
+829.24K
+15.30%
Sep 30, 2025
Capital International Investors
5.65M
5.93%
+55.51K
+0.99%
Sep 30, 2025
Orbis Investment Management Ltd.
4.98M
5.23%
+2.22M
+80.21%
Sep 30, 2025
State Street Investment Management (US)
4.01M
4.2%
+736.64K
+22.52%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
3.28M
3.44%
-400.44K
-10.87%
Sep 30, 2025
UBS Financial Services, Inc.
2.28M
2.4%
-302.69K
-11.70%
Sep 30, 2025
The Vanguard Group, Inc.
2.35M
2.46%
+66.56K
+2.92%
Sep 30, 2025
Amova Asset Management Americas, Inc
2.16M
2.27%
-250.60K
-10.38%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.14M
2.25%
+69.29K
+3.34%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
ARK Genomic Revolution ETF
10.33%
Global X Genomics & Biotechnology ETF
5.71%
ARK Innovation ETF
5.12%
AXS Green Alpha ETF
4.84%
WisdomTree BioRevolution Fund
2.81%
Virtus LifeSci Biotech Products ETF
2.48%
State Street SPDR S&P Biotech ETF
2.41%
Direxion Daily S&P Biotech Bull 3X Shares
1.48%
Franklin Genomic Advancements ETF
0.92%
ProShares Ultra Nasdaq Biotechnology
0.59%
Ver Mais
ARK Genomic Revolution ETF
Proporção10.33%
Global X Genomics & Biotechnology ETF
Proporção5.71%
ARK Innovation ETF
Proporção5.12%
AXS Green Alpha ETF
Proporção4.84%
WisdomTree BioRevolution Fund
Proporção2.81%
Virtus LifeSci Biotech Products ETF
Proporção2.48%
State Street SPDR S&P Biotech ETF
Proporção2.41%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção1.48%
Franklin Genomic Advancements ETF
Proporção0.92%
ProShares Ultra Nasdaq Biotechnology
Proporção0.59%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
